Search Results - Shuni Wang

  • Showing 1 - 2 results of 2
Refine Results
  1. 1

    Safety, tolerability, and pharmacokinetics of an anti-LAG-3 antibody SHR-1802 in patients with advanced solid tumors: a phase I dose-escalation and dose-expansion study by Ting Deng, Zhigang Liu, Zhengquan Han, Huan Zhou, Rui Liu, Yijing Li, Shaorong Li, Peng Xiu, Shuni Wang, Yiping Zhang, Yi Ba

    Published in Therapeutic Advances in Medical Oncology (2023-07-01)
    Get full text
    Article


  2. 2

    First-line treatment with camrelizumab plus famitinib in advanced or metastatic NSCLC patients with PD-L1 TPS ≥1%: results from a multicenter, open-label, phase 2 trial by Ying Liu, Jia Fan, Jun Zhao, Tianshu Liu, Caicun Zhou, Shengxiang Ren, Ying Cheng, Caigang Liu, Xicheng Wang, Sheng Hu, Yufeng Cheng, Yueyin Pan, Shegan Gao, Yalun Li, Bao-Hui Han, Jifeng Feng, Shanyong Yi, Shanzhi Gu, Yongzhong Luo, Huijie Duan, Shuni Wang, Xinfeng Yang

    Published in Journal for ImmunoTherapy of Cancer (2024-02-01)
    Get full text
    Article


Search Tools: